Page 17 - Morphosys News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Morphosys. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Morphosys Today - Breaking & Trending Today

EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi (tafasitamab-cxix)

16.04.2023 - EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi (tafasitamab-cxix) 16.04.2023 / . ....

United States , University Hospital , Johannes Duell , Tim Demuth , Steven Stein , Morphosys Us Inc , Xencor Inc , News Service , Practice Research Clinical Haematology , American Association For Cancer Research Annual Meeting , Distribution Services , Tradegate Exchange , American Association For Cancer Research , Exchange Commission , Drug Administration , Incyte Announce Five Year Results , Showed Prolonged , Durable Responses , American Association , Cancer Research Annual Meeting , Annual Meeting , Medical Clinic , Chief Research , Development Officer , Chief Medical Officer , Diffuse Largeb Cell Lymphoma ,

MorphoSys (ETR:MOR) Trading 13.4% Higher

Shares of MorphoSys AG (ETR:MOR – Get Rating) traded up 13.4% during mid-day trading on Thursday . The company traded as high as €17.11 ($18.60) and last traded at €16.59 ($18.03). 289,931 shares were traded during trading, an increase of 89% from the average session volume of 153,687 shares. The stock had previously closed at […] ....

United States , Jpmorgan Chase Co , Goldman Sachs Group , Morgan Stanley , Get Rating , Morphosys Daily , Petr Mor ,

MorphoSys (NASDAQ:MOR) Shares Gap Down to $4.59

MorphoSys AG (NASDAQ:MOR – Get Rating) gapped down prior to trading on Thursday . The stock had previously closed at $4.59, but opened at $4.46. MorphoSys shares last traded at $4.42, with a volume of 36,782 shares. Analyst Upgrades and Downgrades MOR has been the topic of several research analyst reports. JPMorgan Chase & Co. […] ....

Virtu Financial , Citadel Advisors , Jpmorgan Chase Co , Morgan Stanley , Goldman Sachs Group , Susquehanna International Group , Optiver Holding , Get Rating , International Group , Morphosys Daily , Nasdaq Mor ,

Morphosys to present data on hope drug earlier

Morphosys is making faster progress than expected with research on its hopeful drug Pelabresib. Key results from the pivotal Phase 3 trial of its drug for the rare bone marrow cancer myelofibrosis. | April 5, 2023 ....

James Gordon , Tim Demuth , Constellation Pharmaceuticals , Morphosys Ag Stock Exchange , Press Release , Ancer Mor De0006632003 ,

MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023

EQS-News: MorphoSys AG

/ Key word: Miscellaneous

MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023. | April 4, 2023 ....

United States , Italy General , Julia Neugebauer , Tim Demuth , Eamonn Nolan , Thomas Biegi , American Society Of Hematology , German Lymphoma Association , Drug Administration , Constellation Pharmaceuticals Inc , Xencor Inc , Us Oncology Network , Exchange Commission , Sys Completes Enrollment , Topline Results Expected , Chief Research , Development Officer , Myelofibrosis Symptom Assessment Form , American Society , Constellation Pharmaceuticals , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Medication Guide , Prescribing Information , Patient Information , Important Safety ,